TRDA ENTRADA THERAPEUTICS INC

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nathan Dowden, Chief Operating Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 – 14, 2022.

The company’s presentation will be available to view beginning on Monday, September 12, 2022 at 7:00 a.m. Eastern Time on the Investor Relations section of the Company’s website at . A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, , and follow us on  and .

Investor and Media Contact

Karla MacDonald

Chief Corporate Affairs Officer



EN
30/08/2022

Underlying

TRDAENTRADA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENTRADA THERAPEUTICS INC

 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Independent Data Monitoring Committee Recommends Initiation of Cohort ...

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study -- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight pat...

February 17, 2026 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to Present at Upcoming Investor Conferences BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Easte...

February 4, 2026 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-b...

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases -- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and exp...

January 8, 2026 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthc...

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at . The webcast will be archived and available for replay for 30 days after the event. About Entrada Therapeutics...

December 17, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of December 1, 2025. The options have an exercise price of $9.91 per share, which is equal to the closing price of the Company's co...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch